10-Q: Edesa Biotech Reports Q3 2025 Financial Results

Edesa Biotech reports a net loss of $1.7 million, or $0.25 per common share, for Q3 2025, with a focus on advancing its vitiligo program.

Summary

• Edesa Biotech reported a net loss of $1.7 million, or $0.25 per common share, for the three months ended June 30, 2025, compared to a net loss of $1.7 million, or $0.52 per common share, for the three months ended June 30, 2024.
• Research and development expenses were $0.9 million for both the three months ended June 30, 2025 and 2024.
• General and administrative expenses were $1.0 million for both the three months ended June 30, 2025 and 2024.
• The company had cash and cash equivalents of $12.4 million as of June 30, 2025, and working capital of $12.1 million.
• The company expects its cash and cash equivalents will be used to fund operating expenses including the advancement of the vitiligo program through the end of fiscal 2026.
• Gross proceeds of $15.0 million were received from the sale of preferred shares and common shares in a private placement and $1.5 million from the sale of preferred shares to an entity controlled by the company's CEO during the nine month period ended June 30, 2025.

Sentiment

Score: 4

Explanation: The filing contains both positive and negative aspects. The company has a strong cash position, but it is also incurring losses and needs to raise additional capital. The company is also facing delays in its clinical trials.

Positives

• Cash and cash equivalents increased significantly to $12.4 million as of June 30, 2025, compared to $1.0 million as of September 30, 2024.
• Working capital increased to $12.1 million as of June 30, 2025, compared to $1.7 million as of September 30, 2024.
• The company received $15.0 million in gross proceeds from the sale of common shares and Series B-1 Preferred Shares in a private placement.
• The company received $1.5 million from the sale of Series A-1 Preferred Shares to an entity controlled by the company's CEO.
• The company expects its cash and cash equivalents will be used to fund operating expenses including the advancement of the vitiligo program through the end of fiscal 2026.

Negatives

• The company incurred a net loss of $1.7 million for the three months ended June 30, 2025.
• The company has an accumulated deficit of $63.6 million as of June 30, 2025.
• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• The company expects to continue to incur substantial additional operating losses for at least the next several years.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates.
• There can be no assurance that the company will be successful in raising the necessary financing.
• The company expects to continue to incur substantial additional operating losses for at least the next several years as it continues to develop its product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of its product candidates.
• Adequate funding may not be available to the company on acceptable terms, or at all. If the company fails to raise capital or enter into such agreements as and when needed, it may have to significantly delay, scale back or discontinue the development of its product candidates.

Future Outlook

The company expects that its cash and cash equivalents at June 30, 2025, including the net proceeds from the Series A-1 Purchase Agreement, the $15.0 million in gross proceeds from the sale of common shares and Series B-1 Preferred Shares, HCW ATM and reimbursements of eligible R&D expenses under the 2023 SIF Agreement will be used to fund its operating expenses including the advancement of the vitiligo program through the end of fiscal 2026.

Management Comments

• "We anticipate data to be submitted to the FDA by the end of calendar 2025 based on the current availability of manufacturing slots at third party service providers."
• "During the third fiscal quarter, the U.S. government announced that the first randomizations of EB05 and other host directed therapeutics were completed."

Industry Context

Edesa Biotech is focused on developing innovative therapeutics for inflammatory and immune-related diseases, which aligns with the broader industry trend of targeting these diseases with novel approaches. The company's focus on host-directed therapeutics (HDTs) for respiratory diseases is also in line with the growing interest in this area.

Comparison to Industry Standards

• The company's cash position of $12.4 million is relatively low compared to other clinical-stage biopharmaceutical companies.
• The company's R&D expenses of $0.9 million for the quarter are also relatively low compared to other clinical-stage biopharmaceutical companies.
• The company's net loss of $1.7 million for the quarter is comparable to other clinical-stage biopharmaceutical companies.
• The company's reliance on government grants and private placements for funding is common among clinical-stage biopharmaceutical companies.

Related Party Transactions

• The company's Chief Executive Officer, Secretary, and a member of the board of directors purchased 100 Series B-1 Preferred Shares for an aggregate purchase price of $1.0 million.
• A director purchased 41,666 Common Shares for an aggregate purchase price of approximately $80,000.
• Another director purchased 10,416 Common Shares for an aggregate purchase price of approximately $20,000.
• Entities affiliated with significant beneficial owners purchased, in aggregate, 2,687,500 Common Shares and 734 Series B-1 Preferred Shares for aggregate gross proceeds of approximately $12.5 million.
• The company entered into the Series A-1 Purchase Agreement with the Series A-1 Purchaser, an entity controlled by the company's Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to the Series A-1 Purchaser in a private placement, up to $5,000,000 of the Series A-1 Preferred Shares.
• The company paid cash of $20,000 and $60,000 in 2025, and $20,000 and $60,000 in 2024, respectively, for a lease from a company controlled by the company's CEO.

Stakeholder Impact

• Shareholders will experience dilution if the company raises additional funds by issuing equity securities.
• The company's ability to continue as a going concern is dependent on obtaining additional funding, which could impact employees, customers, and suppliers.
• The company's strategic transactions could materially affect its liquidity and capital resources, which could impact stakeholders.

Next Steps

• Advance the vitiligo program through the end of fiscal 2026.
• Seek additional financing through the sale of equity, government grants, debt financings or other capital sources, including potential future licensing, collaboration or similar arrangements with third parties or other strategic transactions.
• Continue to evaluate a wide array of strategic transactions as part of the company's plan to acquire or in license and develop additional products and product candidates to augment its internal development pipeline.

Key Dates

Recommendation

The company has a strong cash position, but it is also incurring losses and needs to raise additional capital. The company is also facing delays in its clinical trials. Therefore, a hold recommendation is appropriate.

Keywords

Edesa Biotech, biopharmaceutical, EB06, EB05, vitiligo, ARDS, financial results, clinical trials, preferred shares, common shares